← Back to Clinical Trials
Recruiting NCT07392905

Food Intake-Related Brain and Metabolic Responses in Obesity

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Obesity
Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age 40 Years
Start Date 2025-12-21
Completion 2027-09-01
Interventions
Glucose Liquid MealFat Liquid MealProtein Liquid Meal

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is a prospective, single-center, randomized, controlled, crossover intervention trial. A total of 60 participants, including 30 patients with obesity and 30 healthy controls, will be enrolled. Each participant will receive an isocaloric liquid meal challenge (glucose, fat, or protein) on three separate experimental days, with a washout period of at least 7 days between visits to eliminate carryover effects from the previous intervention. The primary objective is to investigate the association between brain functional patterns and plasma metabolic profiles following the ingestion of different macronutrients in patients with obesity, aiming to uncover potential neuro-metabolic imbalance features.

Eligibility Criteria

Inclusion Criteria: Obese participants: 1. BMI ≥ 28 kg/m²; 2. Age 18-40 years; 3. Any gender; 4. Right-handed. Healthy control participants: 1. BMI 18.5-23.9 kg/m²; 2. Age 18-40 years; 3. Any gender; 4. Right-handed. Exclusion Criteria: 1. Diabetes mellitus; 2. Contraindications or allergies to any ingredient in the standardized meal or macronutrient challenges used in this study; 3. Central nervous system disorders (e.g., traumatic brain injury, acute cerebral infarction, epilepsy) or psychiatric disorders (e.g., depression, schizophrenia); use of medications acting on the central nervous system within the past 3 months or long-term use; 4. Severe impairment of liver, kidney, heart, or gastrointestinal function, including alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels \>2 times the upper limit of normal; estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m² calculated by the CKD-EPI equation; history of unstable angina or myocardial infarction

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology